Dr. Reddy’s Laboratories launches DailyBloom IBS : India’s first integrated care plan for irritable bowel syndrome
Dr. Reddy’s Laboratories Ltd., a globally recognized pharmaceutical company, has unveiled DailyBloom IBS, marking a significant advancement in the management of Irritable Bowel Syndrome (IBS) in India. Launched on World IBS Day, DailyBloom IBS is the first comprehensive care plan in India tailored specifically for IBS, incorporating a mobile application developed in-house for continuous care.
Comprehensive Features of DailyBloom IBS:
The DailyBloom IBS program offers a 14-week personalized care plan that begins with an initial assessment through the DailyBloom Gut Health Index. This assessment helps capture the frequency of IBS symptoms and their impact on patients’ quality of life. Following this, patients partake in goal-setting sessions that tailor their treatment pathways to their specific health objectives and lifestyle preferences. This level of personalization is essential for effectively managing a complex condition like IBS, which is characterized by abdominal pain, bloating, and altered bowel habits.
Dr. Reddy’s Laboratories launches DailyBloom IBS, India’s first integrated care plan for IBS to revolutionize patient care with innovative health solutions.
Support Through Integrated Care:
Patients enrolled in the DailyBloom IBS program will benefit from over 16 consultations with certified nutritionists, psychologists, and care managers, supplemented by unlimited chat support. The care plan also provides access to more than 500 gut-friendly recipes, enhancing dietary management, which is a crucial component of IBS treatment. This integrated approach is designed to address not only the physical symptoms of IBS but also the psychological aspects, which are often significant.
Expert Collaboration and Research-Driven Development:
The development of DailyBloom IBS involved extensive research, including 9,600+ minutes of doctor and patient interactions and over 3,000 observations to pinpoint more than 300 pain points associated with IBS. This rigorous process, guided by insights from multidisciplinary experts, gastroenterologists, and patient feedback, underscores the program’s foundation on scientifically validated principles.
Strategic Focus of Dr. Reddy’s:
M.V. Ramana, Chief Executive Officer of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, highlighted the strategic vision behind DailyBloom IBS, linking it to the company’s broader objectives. “Apart from growing our core business, our strategy for India is based on the innovative pillars of access to novel molecules, consumer health, and digital therapeutics. DailyBloom IBS aligns with our commitment to meeting the unmet needs of patients and enhancing the standard of care,” said Ramana. This initiative is part of Dr. Reddy’s long-standing leadership in the gastrointestinal sector and complements their established pharmaceutical products.
The launch of DailyBloom IBS by Dr. Reddy’s Laboratories represents a pivotal shift towards integrated, technology-driven healthcare solutions in India, promising improved quality of life for patients suffering from IBS. It showcases the company’s commitment to innovation and patient-centered care in the digital therapeutics landscape.